Testing three medications together for a blood cancer with a specific genetic mutation

This trial is testing a combination of three medications—ASTX727, venetoclax, and gilteritinib—to treat a type of blood cancer called acute myeloid leukemia (AML) or a related blood disorder called myelodysplastic syndrome (MDS) that have a specific genetic change called an FLT3 mutation. The trial is divided into two parts: first, researchers will find the safest and most effective dose of the medication combination, then they will test how well it works in treating newly diagnosed or previously treated patients.

Some blood cancers are harder to treat because they have an FLT3 mutation, and patients don't always respond well to standard treatments. This trial exists to see if combining three different medications—each one that targets the cancer in different ways—might work better than treatments currently available.